31 recruiting, 24 completed, 11 active not recruiting, 11 unknown. 38 Phase 2, 22 Phase 1, 8 Not applicable, 8 Phase 3, 1 Phase 4.
Follow Breast Cancer Metastatic: new trials by email Literature Review of Breast Cancer Metastatic trials Research Report on Breast Cancer Metastatic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Plant-Based Nutrition for Breast or Endometrial Cancer Control, Whole Food, Plant-Based Diet with Behavioral Education and Support - Breast Cancer Metastatic, Endometrial Cancer Stage IV | Not applicable | Not yet recruiting | University of Rochester | 60 | 2026-12-01 | 2026-04-08 |
| Screening for Brain Metastases gadopiclenol (contrast agent), standard contrast agent - Lung Cancer Stage IV, Melanoma Stage IV | Phase 2 | Not yet recruiting | University of Zurich | 180 | 2026-09-01 | 2026-03-25 |
| Nectin-4 PET to Predict Response to Nectin-4-Targeted Therapy in Advanced Breast Cancer Breast Cancer Metastatic | Active not recruiting | Fudan University | 40 | 2026-06-30 | 2026-07-16 | |
| Decision Support Tool for Patients With Advanced Breast Cancer Decision Support Tool - Breast Cancer Metastatic, Advanced Breast Cancer | Not applicable | Recruiting | Weill Medical College of Cornell University | 100 | 2026-06-17 | 2026-08-19 |
| Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer Ribociclib with fulvestrant, Physician's choice treatments group - Breast Cancer Metastatic | Phase 2 | Not yet recruiting | Yeon Hee Park | 272 | 2026-02-01 | 2025-12-24 |
| First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients. Sacituzumab Govitecan (SG) - Advanced Triple Negative Breast Cancer, Breast Cancer Metastatic | Phase 2 | Recruiting | Nathalie Levasseur | 24 | 2026-01-20 | 2026-10-06 |
| Nutrition Awareness Among Women With Non-Metastatic Breast Cancer Educational Brochure - Breast Cancer, Breast Cancer Metastatic | Not applicable | Recruiting | UNC Lineberger Comprehensive Cancer Center | 200 | 2026-01-20 | 2026-02-05 |
| Sapu003 in Advanced mTOR-sensitive Solid Tumors Sapu003, Exemestane 25 MG - Breast Cancer Metastatic, Renal Cell Carcinoma (RCC) | Phase 1 | Recruiting | SAPU NANO (US) LLC | 27 | 2025-12-15 | 2026-01-27 |
| A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1 humanized monoclonal anti-FGFR1 antibody OM-RCA-01 - Renal Cell Carcinoma Metastatic, Prostate Cancer Metastatic | Phase 1 / Phase 2 | Recruiting | Kidney Cancer Research Bureau | 58 | 2025-12-02 | 2026-01-21 |
| Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy Avasopasem - Breast Cancer Metastatic | Phase 1 | Recruiting | The University of Texas Health Science Center at San Antonio | 35 | 2025-10-02 | 2025-10-31 |
| A Real-World Study in Patients With HR+/HER2- Advanced Breast Cancer Breast Cancer Metastatic, HR+/HER2- Advanced Breast Cancer | Withdrawn | SciClone Pharmaceuticals | 2025-08-01 | 2025-11-28 | ||
| Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy trastuzumab derxutecan - Breast Cancer Metastatic, Breast Cancer Stage IV | Phase 2 | Enrolling by invitation | UNICANCER | 80 | 2025-07-30 | 2026-08-03 |
| Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer Sacituzumab Govitecan with pegfilgrastim - Breast Cancer Metastatic | Phase 2 | Recruiting | Yeon Hee Park | 40 | 2025-07-03 | 2025-08-28 |
| Trial of Trastuzumab Deruxtecan in Previously Treated HER2 Trastuzumab Deruxtecan - Breast Cancer Metastatic | Phase 2 | Recruiting | Yale University | 40 | 2025-06-20 | 2026-09-03 |
| A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2-expressing Metastatic Breast Cancer. ES2B-C001, ISA 51 VD - Breast Cancer, Breast Cancer Metastatic | Phase 1 | Active not recruiting | ExpreS2ion Biotechnologies | 40 | 2025-06-03 | 2026-09-18 |
| A Phase II Study of SHR-A1811 Combined With Radiotherapy in HER2-positive and HER2-low Breast Cancer Brain Metastases SHR-A1811 and radiotherapy - Breast Cancer Metastatic | Phase 2 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 30 | 2025-06-01 | 2025-05-16 |
| Efficacy and Safety of DS8201 in Metastatic Breast Cancer's Treatment Breast Cancer Metastatic, Efficacy and Safety | Enrolling by invitation | The First Hospital of Jilin University | 200 | 2025-05-25 | 2025-07-08 | |
| A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer Two Component Product CLBR001 + ABBV-461 - Breast Cancer Metastatic, Locally Advanced Breast Cancer (LABC) | Phase 1 | Terminated | Calibr, a division of Scripps Research | 10 | 2025-04-17 | 2026-05-28 |
| Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer Zoledronic Acid Combined with Neoadjuvant Chemotherapy (EC-T) - Breast Cancer Metastatic | Not applicable | Active not recruiting | Xijing Hospital | 99 | 2025-03-10 | 2025-07-29 |
| Rapid Assessment of Sentinel Lymph Node Metastasis Status Using a Pan-CK-targeting NIR-II Fluorescent Probe in Breast Cancer NIR-II probe (i.e ICG-CK) incubation solution - Breast Cancer Metastatic, Sentinel Lymph Node | Recruiting | Yunnan Cancer Hospital | 60 | 2025-02-01 | 2025-09-04 |
Showing 20 of 94. Sign in to see all of them.
Breast Neoplasms (42) · Neoplasm Metastasis (10) · Triple Negative Breast Neoplasms (4) · Endometrial Neoplasms (3) · Neoplasms (3) · Brain Neoplasms (2) · Communication (2) · Head and Neck Neoplasms (2) · Lung Neoplasms (2) · Ovarian Neoplasms (2) · Recurrence (2) · Acrocephalosyndactylia (1) · Ascites (1) · Breast Cancer Lymphedema (1) · Carcinoma, Hepatocellular (1)
Neoplasms by Site (47) · Neoplasms (45) · Skin Diseases (43) · Skin and Connective Tissue Diseases (43) · Breast Diseases (42) · Pathologic Processes (13) · Pathological Conditions, Signs and Symptoms (13) · Neoplastic Processes (10) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Urogenital Diseases (6) · Urogenital Neoplasms (6) · Genital Diseases (5) · Genital Diseases, Female (4) · Genital Neoplasms, Female (4)
Fulvestrant (8) · Letrozole (6) · Trastuzumab (6) · exemestane (5) · Anastrozole (4) · Capecitabine (4) · Cyclophosphamide (4) · Docetaxel (4) · Paclitaxel (4) · Ado-Trastuzumab Emtansine (3) · Radiotherapy (3) · abemaciclib (3) · dalpiciclib (3) · olaparib (3) · palbociclib (3)
Fudan University (7) · MedSIR (3) · Sanofi (3) · BriaCell Therapeutics Corporation (2) · I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio (2) · Istituto Oncologico Veneto IRCCS (2) · Nanogen Pharmaceutical Biotechnology Joint Stock Company (2) · Pfizer (2) · Yeon Hee Park (2) · Zhejiang Cancer Hospital (2) · Adrienne G. Waks (1) · Affiliated Hospital to Academy of Military Medical Sciences (1) · AstraZeneca (1) · Calibr, a division of Scripps Research (1) · Centre de recherche du Centre hospitalier universitaire de Sherbrooke (1)
China (28) · United States (26) · Italy (12) · Spain (9) · France (6) · South Korea (6) · United Kingdom (5) · Australia (4) · Canada (4) · Russia (4) · Taiwan (4) · Turkey (Türkiye) (4) · Argentina (3) · Belgium (3) · Germany (3)
Adriana Kahn, M.D. (1) · Adrienne Waks, MD (1) · Alessandra Fabi (1) · Alexandra Thomas, MD (1) · Alfredo Quinones Hinojosa, MB (1) · Alphonse G. Taghian, MD (1) · Antonio Llombart (1) · Antonio Llombart-Cussac (1) · Arnold Glazier, M.D. (1) · Bing Sun, M.D. (1) · Biyun Wang, Chief physician (1) · Bushra Shirazi (1) · C. Kent Osborne, MD (1)
PMID 10561296, PMID 11396203, PMID 15020608, PMID 15139054, PMID 15800309, PMID 15911866, PMID 16149088, PMID 16597163, PMID 16736568, PMID 17033039, PMID 18515736, PMID 19884557, PMID 19916733, PMID 20038734, PMID 23393171, PMID 23764181, PMID 24693229, PMID 2470152, PMID 25075022, PMID 26674923, PMID 27659537, PMID 28076709, PMID 28294295, PMID 28450563, PMID 28578601, PMID 28912116, PMID 29503845, PMID 31917762, PMID 37348019, PMID 37415239, PMID 37690320, PMID 37843531, PMID 3798106, PMID 38751523, PMID 39270828, PMID 39692755, PMID 40439892, PMID 41670750, PMID 7819273, PMID 9256133, PMID 9752815
2016 (2), 2017 (2), 2018 (1), 2023 (1), R21CA208968 (1)